A double - blind , randomized , controlled , multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">chronic_2</font> <font color="red">heart_2</font> <font color="red">failure_2</font> <font color="red">after_2</font> <font color="red">myocardial_2</font> <font color="red">infarction_2</font> <font color="red">._2</font> <font color="red">
<br>
<br>_1</font> BACKGROUND We sought to determine the safety and preliminary efficacy of transcatheter intramyocardial administration of myoblasts in <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">heart_2</font> <font color="red">failure_2</font> <font color="red">(_2</font> <font color="red">HF_2</font> <font color="red">)_2</font> <font color="red">._2</font> <font color="red">
<br>_1</font> METHODS MARVEL is a randomized placebo - controlled trial of image - guided , catheter - based intramyocardial injection of placebo or myoblasts ( 400 or 800 million ) in <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">class_2</font> <font color="red">II_2</font> <font color="red">to_2</font> <font color="red">IV_2</font> <font color="red">HF_2</font> <font color="red">and_2</font> <font color="red">ejection_2</font> <font color="red">fraction_2</font> <font color="red"><_2</font> <font color="red">35%_2</font> <font color="red">._2</font> Primary end points were frequency of serious adverse events ( safety ) and changes in 6-minute walk test and Minnesota Living With HF score ( efficacy ) . <font color="red">Of_1</font> <font color="red">330_2</font> <font color="red">patients_2</font> <font color="red">intended_2</font> <font color="red">for_2</font> <font color="red">enrollment_2</font> <font color="red">,_2</font> <font color="red">23_2</font> <font color="red">were_2</font> <font color="red">randomized_2</font> <font color="red">(_2</font> <font color="red">MARVEL-1_2</font> <font color="red">)_2</font> <font color="red">before_2</font> <font color="red">stopping_2</font> <font color="red">the_2</font> <font color="red">study_2</font> <font color="red">for_2</font> <font color="red">financial_2</font> <font color="red">reasons_2</font> <font color="red">._2</font> <font color="red">
<br>_1</font> RESULTS At 6 months , similar numbers of events occurred in each group : 8 ( placebo ) , 7 ( low dose ) , and 8 ( high dose ) , without deaths . Ventricular tachycardia responsive to amiodarone was more frequent in myoblast - treated patients : 1 ( placebo ) , 3 ( low dose ) , and 4 ( high dose ) . A trend toward improvement in functional capacity was noted in myoblast - treated groups ( Î”6-minute walk test of -3.6 vs + 95.6 vs + 85.5 m [ placebo vs low dose vs high dose ; P = .50 ] ) without significant changes in Minnesota Living With HF scores . 
<br> CONCLUSIONS In <font color="red">HF_2</font> <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">chronic_2</font> <font color="red">postinfarction_2</font> <font color="red">cardiomyopathy_2</font> <font color="red">,_2</font> transcatheter administration of myoblasts in doses of 400 to 800 million cells is feasible and may lead to important clinical benefits . Ventricular tachycardia may be provoked by myoblast injection but appears to be a transient and treatable problem . A large - scale outcome trial of myoblast administration in <font color="red">HF_2</font> <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">postinfarction_2</font> <font color="red">cardiomyopathy_2</font> is feasible and warranted .